Literature DB >> 23722241

Allosteric modulation of GABA(A) receptor subtypes:effects on visual recognition and visuospatial working memory in rhesus monkeys [corrected].

Paul L Soto1, Nancy A Ator, Sundari K Rallapalli, Poonam Biawat, Terry Clayton, James M Cook, Michael R Weed.   

Abstract

Non-selective positive allosteric modulators (PAMs) of GABAA receptors (GABAARs) are known to impair anterograde memory. The role of the various GABAAR subtypes in the memory-impairing effects of non-selective GABAAR PAMs has not been fully elucidated. The current study assessed, in rhesus monkeys, effects of modulation of α1, α2/3, and α5GABAARs on visual recognition and spatial working memory using delayed matching-to-sample (DMTS) and self-ordered spatial search (SOSS) procedures, respectively. The DMTS procedure (n=8) involved selecting a previously presented 'sample' image from a set of multiple images presented after a delay. The SOSS procedure (n=6) involved touching a number of boxes without repeats. The non-selective GABAAR PAM triazolam and the α1GABAA preferential PAMS zolpidem and zaleplon reduced accuracy in both procedures, whereas the α5GABAA preferential PAMs SH-053-2'F-R-CH3 and SH-053-2'F-S-CH3, and the α2/3GABAA preferential PAM TPA023B were without effects on accuracy or trial completion. The low-efficacy α5GABAAR negative allosteric modulator (NAM) PWZ-029 slightly increased only DMTS accuracy, whereas the high-efficacy α5GABAAR NAMs RY-23 and RY-24 did not affect accuracy under either procedure. Finally, the slopes of the accuracy dose-effect curves for triazolam, zolpidem, and zaleplon increased with box number in the SOSS procedure, but were equivalent across DMTS delays. The present results suggest that (1) α1GABAARs, compared with α2/3 and α5GABAARs, are primarily involved in the impairment, by non-selective GABAAR PAMs, of visual recognition and visuospatial working memory in nonhuman primates; and (2) relative cognitive impairment produced by positive modulation of GABAARs increases with number of locations to be remembered, but not with the delay for remembering.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23722241      PMCID: PMC3773684          DOI: 10.1038/npp.2013.137

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  47 in total

1.  Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment.

Authors:  Ming Teng Koh; Sharon Rosenzweig-Lipson; Michela Gallagher
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

2.  Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure.

Authors:  Bradford D Fischer; Stephanie C Licata; Rahul V Edwankar; Zhi-Jian Wang; Shengming Huang; Xiaohui He; Jianming Yu; Hao Zhou; Edward M Johnson; James M Cook; Roman Furtmüller; Joachim Ramerstorfer; Werner Sieghart; Bryan L Roth; Samarpan Majumder; James K Rowlett
Journal:  Neuropharmacology       Date:  2010-08-18       Impact factor: 5.250

3.  Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist.

Authors:  J R Atack; D J Hallett; S Tye; K A Wafford; C Ryan; S M Sanabria-Bohórquez; Wai-Si Eng; R E Gibson; H D Burns; G R Dawson; R W Carling; L J Street; A Pike; I De Lepeleire; K Van Laere; G Bormans; J N de Hoon; A Van Hecken; R M McKernan; M G Murphy; R J Hargreaves
Journal:  J Psychopharmacol       Date:  2010-02-15       Impact factor: 4.153

Review 4.  GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics.

Authors:  John R Atack
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 5.  GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.

Authors:  John R Atack
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

6.  Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use.

Authors:  Bethea A Kleykamp; Roland R Griffiths; Una D McCann; Michael T Smith; Miriam Z Mintzer
Journal:  Exp Clin Psychopharmacol       Date:  2011-09-19       Impact factor: 3.157

7.  Reversal of ketamine-induced working memory impairments by the GABAAalpha2/3 agonist TPA023.

Authors:  Stacy A Castner; Jeffrey L Arriza; John C Roberts; Ladislav Mrzljak; Edward P Christian; Graham V Williams
Journal:  Biol Psychiatry       Date:  2010-02-26       Impact factor: 13.382

8.  Delayed match-to-sample performance in African green monkeys (Chlorocebus aethiops sabaeus): effects of benzodiazepine, cholinergic, and anticholinergic drugs.

Authors:  Todd M Myers; Lindsey R Hamilton
Journal:  Behav Pharmacol       Date:  2011-12       Impact factor: 2.293

Review 9.  Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.

Authors:  John R Atack
Journal:  Pharmacol Ther       Date:  2009-09-19       Impact factor: 12.310

10.  Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at alpha1 plus alpha5 versus alpha2 plus alpha3 subunits account for dissimilarities in behavioral effects in rats?

Authors:  Miroslav M Savić; Samarpan Majumder; Shengming Huang; Rahul V Edwankar; Roman Furtmüller; Srdan Joksimović; Terry Clayton; Joachim Ramerstorfer; Marija M Milinković; Bryan L Roth; Werner Sieghart; James M Cook
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-01-13       Impact factor: 5.067

View more
  11 in total

1.  Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABAA receptors containing the α5 subunit.

Authors:  Tamara Timić Stamenić; Michael M Poe; Sabah Rehman; Anja Santrač; Branka Divović; Petra Scholze; Margot Ernst; James M Cook; Miroslav M Savić
Journal:  Eur J Pharmacol       Date:  2016-09-14       Impact factor: 4.432

2.  Emergence delirium with transient associative agnosia and expressive aphasia reversed by flumazenil in a pediatric patient.

Authors:  Julie K Drobish; Max B Kelz; Patricia M DiPuppo; Scott D Cook-Sather
Journal:  A A Case Rep       Date:  2015-06-01

3.  Behavioral pharmacology of the odor span task: Effects of flunitrazepam, ketamine, methamphetamine and methylphenidate.

Authors:  Mark Galizio; Brooke April; Melissa Deal; Andrew Hawkey; Danielle Panoz-Brown; Ashley Prichard; Katherine Bruce
Journal:  J Exp Anal Behav       Date:  2016-10-17       Impact factor: 2.468

4.  Olfactory Stimulus Control and the Behavioral Pharmacology of Remembering.

Authors:  Mark Galizio
Journal:  Behav Anal (Wash D C)       Date:  2016-03-17

5.  Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion.

Authors:  Tamara Timić Stamenić; Srdjan Joksimović; Poonam Biawat; Tamara Stanković; Bojan Marković; James M Cook; Miroslav M Savić
Journal:  J Psychopharmacol       Date:  2015-06-23       Impact factor: 4.153

Review 6.  GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.

Authors:  Meng-Yi Xu; Albert H C Wong
Journal:  Acta Pharmacol Sin       Date:  2018-03-22       Impact factor: 6.150

7.  Amnestic drugs in the odor span task: Effects of flunitrazepam, zolpidem and scopolamine.

Authors:  Mark Galizio; Michael Mathews; Madeleine Mason; Danielle Panoz-Brown; Ashley Prichard; Paul Soto
Journal:  Neurobiol Learn Mem       Date:  2017-09-08       Impact factor: 2.877

Review 8.  Disinhibition, an emerging pharmacology of learning and memory.

Authors:  Hanns Möhler; Uwe Rudolph
Journal:  F1000Res       Date:  2017-02-03

9.  The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats.

Authors:  Stephen R Morairty; Alan J Wilk; Webster U Lincoln; Thomas C Neylan; Thomas S Kilduff
Journal:  Front Neurosci       Date:  2014-01-31       Impact factor: 4.677

Review 10.  Preclinical animal anxiety research - flaws and prejudices.

Authors:  Abdelkader Ennaceur; Paul L Chazot
Journal:  Pharmacol Res Perspect       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.